E2022

DRUG3 trials

Sponsors

Eisai Co., Ltd.

Conditions

HealthyHealthy SubjectsJapanese Healthy Male Adult Volunteers

Phase 1

E2022 Patch Formulation Single Dose Phase I Study

CompletedNCT01253434

Eisai Co., Ltd.Japanese Healthy Male Adult Volunteers

Start: 2010-11-30End: 2011-03-31Updated: 2013-05-14

E2022 Patch Formulation Multiple Dose Study

CompletedNCT01450839

Eisai Co., Ltd.Healthy

Start: 2011-09-30End: 2012-02-29Updated: 2012-06-01

A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males

CompletedNCT02225288

Eisai Co., Ltd.Healthy Subjects

Start: 2014-09-30End: 2015-02-28Updated: 2015-04-02